ERCC1 Antibody (3H11): sc-53281

ERCC1 Antibody (3H11) is a mouse monoclonal IgG2a antibody that detects ERCC1 in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), and enzyme-linked immunosorbent assay (ELISA). ERCC1, also known as excision repair cross-complementing 1, plays a crucial role in the nucleotide excision repair pathway, which is essential for maintaining genomic stability by repairing DNA damage caused by ultraviolet light and other environmental factors. ERCC1 forms a heterodimer with XPF, another key player in this repair process, and together they function as a structure-specific endonuclease that incises damaged DNA. This incision is vital for the removal of bulky DNA adducts, thereby preventing mutations that could lead to skin cancer and other malignancies. The significance of ERCC1 in DNA repair highlights its potential as a biomarker for cancer susceptibility and treatment response, making anti-ERCC1 antibody (3H11) an invaluable tool for researchers studying DNA repair mechanisms and their implications in disease.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

Contains Mercury: All HRP conjugates (including bundle forms) contain thiomersal, a mercury compound. Do not dispose in trash. Dispose as hazardous chemical waste according to local, state and federal regulations.

Download thiomersal SDS

ERCC1 Antibody (3H11) References:

1. Multiple roles of the ERCC1-XPF endonuclease in DNA repair and resistance to anticancer drugs.  |  Kirschner, K. and Melton, DW. 2010. Anticancer Res. 30: 3223-32. PMID: 20944091
2. Biological and predictive role of ERCC1 polymorphisms in cancer.  |  Formica, V., et al. 2017. Crit Rev Oncol Hematol. 111: 133-143. PMID: 28259288
3. Association between the ERCC1 polymorphism and platinum-based chemotherapy effectiveness in ovarian cancer: a meta-analysis.  |  Tang, N., et al. 2017. BMC Womens Health. 17: 43. PMID: 28623887
4. Meta-analysis showing that ERCC1 polymorphism is predictive of osteosarcoma prognosis.  |  Liu, X., et al. 2017. Oncotarget. 8: 62769-62779. PMID: 28977987
5. Association of ERCC1 Polymorphisms with the Risk of Colorectal Cancer: A Meta-Analysis.  |  Chen, J., et al. 2017. Crit Rev Eukaryot Gene Expr. 27: 267-275. PMID: 29199611
6. Function and Interactions of ERCC1-XPF in DNA Damage Response.  |  Faridounnia, M., et al. 2018. Molecules. 23: PMID: 30563071
7. The splicing factor XAB2 interacts with ERCC1-XPF and XPG for R-loop processing.  |  Goulielmaki, E., et al. 2021. Nat Commun. 12: 3153. PMID: 34039990
8. ERCC1 Overexpression Increases Radioresistance in Colorectal Cancer Cells.  |  Huang, YJ., et al. 2022. Cancers (Basel). 14: PMID: 36230725
9. ATR inhibition overcomes platinum tolerance associated with ERCC1- and p53-deficiency by inducing replication catastrophe.  |  Heyza, JR., et al. 2023. NAR Cancer. 5: zcac045. PMID: 36644397
10. Initiation phase cellular reprogramming ameliorates DNA damage in the ERCC1 mouse model of premature aging.  |  Paine, PT., et al. 2023. Front Aging. 4: 1323194. PMID: 38322248

The preferred ERCC1 antibody is ERCC1 Antibody (D-10): sc-17809.